Oscar Gary Bukstein

Oscar Gary Bukstein

Auto-generated profile, based on publicly available information

Oscar Gary Bukstein

Department of Psychiatry and Behavioral Sciences, Boston Children’s Hospital, Boston, MA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
HWHeather J. Walter
Heather J. Walter
AAA. Reese Abright
A. Reese Abright
OBOscar G. Bukstein
Oscar G. Bukstein
JDJohn Diamond
John Diamond
HKHelene Keable
Helene Keable
CRCarol Rockhill
Carol Rockhill

24 May 2022 in NEJM Evidence
Verified
Journal Article
Closed access
KSKevin M. Simon
Kevin M. Simon
SLSharon Levy
Sharon Levy
OBOscar G. Bukstein
Oscar G. Bukstein
Adolescent substance use is associated with the leading causes of death in this age group: unintentional injury, suicide, and violence. This review describes the impact on neurobiological developme...

10 November 2011 in Child and Adolescent Psychiatry and Mental Health
Verified
Journal Article
Open access
PDF file
CFCristan A Farmer
Cristan A Farmer
LAL Eugene Arnold
L Eugene Arnold
OBOscar G Bukstein
Oscar G Bukstein
RFRobert L Findling
Robert L Findling
KGKenneth D Gadow
Kenneth D Gadow
MAMichael G Aman
Michael G Aman
Background: Polypharmacy (the concurrent use of more than one psychoactive drug) and other combination interventions are increasingly common for treatment of severe psychiatric problems only partly responsive to monotherapy. This practice and research on it raise scientific, clinical, and ethical issues such as additive side effects, interactions, threshold for adding second drug, appropriate target measures, and (for studies) timing of randomization. One challenging area for treatment is severe child aggression. Commonly-used medications, often in combination, include psychostimulants, antipsychotics, mood stabilizers, and alpha-2 agonists, which vary considerably in terms of perceived safety and efficacy. Results: In designing our NIMH-funded trial of polypharmacy, we focused attention on the added benefit of a second drug (risperidone) to the effect of the first (stimulant). We selected these two drugs because their associated adverse events might neutralize each other (e.g., sleep delay and appetite decrease from stimulant versus sedation and appetite increase from antipsychotic). Moreover, there was considerable evidence of efficacy for each drug individually for the management of ADHD and child aggression. The study sample comprised children (ages 6-12 years) with both diagnosed ADHD and disruptive behavior disorder (oppositional-defiant or conduct disorder) accompanied by severe physical aggression. In a staged sequence, the medication with the least problematic adverse effects (stimulant) was openly titrated in 3 weeks to optimal effect. Participants whose behavioral symptoms were not normalized received additional double-blind medication, either risperidone or placebo, by random assignment. Thus children whose behavioral symptoms were normalized with stimulant medication were not exposed to an antipsychotic. All families participated in an empirically-supported parent training program for disruptive behavior, so that the actual comparison was stimulant+parent training versus stimulant+antipsychotic+parent training. Conclusions: We hope that the resolutions of the challenges presented here will be useful to other investigators and facilitate much-needed research on child psychiatric polypharmacy. Trial Registration: ClinicalTrials.gov NCT00796302

1 April 2015 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Open access
CFCristan A. Farmer
Cristan A. Farmer
NBNicole V. Brown
Nicole V. Brown
KGKenneth D. Gadow
Kenneth D. Gadow
LAL. Eugene Arnold
L. Eugene Arnold
DKDavid G. Kolko
David G. Kolko
MAMichael G. Aman
Michael G. Aman
Objective: In this study, we evaluated parent and child characteristics as predictors and moderators of response in the four-site Treatment of Severe Childhood Aggression (TOSCA) study. Methods: A total of 168 children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder (ADHD) were enrolled in a 9-week trial of basic treatment (n=84, stimulant+parent training+placebo) versus augmented treatment (n=84, stimulant+parent training+risperidone). In the initial report, augmented treatment surpassed basic treatment in reducing the primary outcome of disruptive behavior (D-Total) scores. In the current study, we evaluated parent (income, education, family functioning, employment) and child variables (intelligence quotient [IQ], aggression type, comorbid symptomatology) as predictors or moderators, using linear mixed models and the MacArthur guidelines. Results: Higher scores on ADHD symptom severity and callous/unemotional traits predicted better outcome on D-Total regardless of treatment assignment. Two moderators of D-Total were found: Higher anger/irritability symptoms and lower mania scores were associated with faster response, although not better overall effect at endpoint, in the augmented but not the basic group. Several variables moderated response on secondary outcomes (ADHD severity and prosocial behavior), and were characterized by faster response, although not better outcome, in the augmented but not in the basic group. Maternal education moderated outcome on the measure of positive social behavior; children of mothers with less education benefited more from augmented treatment relative to basic than those with more education. Conclusion: Although these findings require validation, they tentatively suggest that augmented treatment works equally well across the entire sample. Nevertheless, certain child characteristics may be useful indicators for the speed of response to augmented treatment.

14 March 2013 in Journal of Abnormal Child Psychology
Verified
Journal Article
Closed access
PDF file
DKDavid J. Kolko
David J. Kolko
OLOliver Lindhiem
Oliver Lindhiem
JHJonathan Hart
Jonathan Hart
OBOscar G. Bukstein
Oscar G. Bukstein

7 September 2012 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
OBOscar Gary Bukstein
Oscar Gary Bukstein
JHJared Head
Jared Head
Introduction: Guanfacine extended release (GXR) is an alpha 1A noradrenergic agonist that has been approved by the FDA for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) as a monotherapy, and as an adjunctive therapy to stimulants for the treatment of ADHD in children and adolescents age 6 – 17. Areas covered: PubMed, the Ovid Medline database, and the PsycInfo database were searched using the term ‘guanfacine'. Results were then limited to criteria such as English and human, from 1990 through December 2011. The resulting yield from the comprehensive literature search was 4391 articles. The titles and abstracts of all articles were reviewed. Studies were selected for full-text review based upon their place in the hierarchy of evidence (e.g., randomized controlled trials), relevance and quality of individual studies, and generalizability to clinical practice. The search was augmented by further search of article reference lists. A total of 15 articles were selected for full-text examination. Expert opinion: Due to the absence of positive evidence for the efficacy of GXR for monotherapy in adolescents, clinicians should be guarded in the use of GXR for monotherapy in adolescents with ADHD. The use of GXR has considerable promise as an adjunct to stimulants for other behavioral conditions associated with ADHD.